Blog

Erman Akkus: ASCO Ed book on mNSCLC without oncogenic alterations

Photoof Erman Akkus from X

May 6, 2024, 19:10

Erman Akkus: ASCO Ed book on mNSCLC without oncogenic alterations

Erman Akkus, medical oncologist at Ankara Medical University, shared on Twitter/X:

“Metastatic NSCLC without oncogenic alterations
ASCO Educational Book

ICI as Monotherapy
ICI as Combination Treatment
ICI-ICI Combination Treatments
Clinical Decision Questions:
Best Approach in PD-L1≥50%
Role for Dual Checkpoint Blockade
Discontinuation Strategies in Long-term Responders to ICI
Second-Line Treatments
Future Approaches
Antibody-drug Conjugates
Chemotherapy-free First-Line Treatments.”

Visit the article website.
Source: Erman Akkus/X

Antibody drug conjugates ASCO cancer cancer treatment Check point Inhibitors chemotherapy Clinical Decision Making combination therapy Erman Akkus immunotherapy Long Term Responders Lung cancer medical oncology monotherapy NSCLC OncoDaily oncogenic alterations Oncology PD-L1 Treatment Strategies

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Isabel Mestres: In a world where the fight against cancer knows no borders, collaboration is not optional - it’s essential

Special Coverage